CD274 and pancreatic neoplasm: Indeed, in a model of pancreatic cancer, the combination of PD-1 and PD-L1 confer a synergistic benefit over either therapy alone.35 Based on the essential role of PD-1/PD-L1 in myeloid cells, it is likely that the success of anti-PD-L1 and anti-PD-1 combined therapy relies both on the disruption of immunosuppressive TAM-T cell crosstalk and on directly reshaping TAM phenotype toward an antitumor profile.